Skip to main content

Anna Hung

Assistant Professor in Population Health Sciences
Population Health Sciences
N/A, N/A, NC 27701

Overview


Anna Hung, PharmD, PhD, MS is a pharmacist and health services researcher interested in payer and patient decision making related to pharmacy benefits. Previously, she collaborated with the Defense Health Agency to evaluate the budgetary impact of their antidiabetic drug formulary changes. She has also worked with a variety of managed care organizations to assess their drug utilization and clinical management programs. Her methodological research interests include health care cost evaluations, quasi-experimental study designs, and stated preference research.

Dr. Hung received her Doctor of Pharmacy, Master of Science, and Doctor of Philosophy from the University of Maryland. Her PhD is in pharmaceutical health services research, with concentrations in pharmacoeconomics, comparative effectiveness research, and patient-centered outcomes research. Prior to joining the Department of Population Health Sciences, she completed a post-doctoral fellowship at the Duke Clinical Research Institute and served as Co-Chief Fellow.

Current Appointments & Affiliations


Assistant Professor in Population Health Sciences · 2020 - Present Population Health Sciences, Basic Science Departments
Core Faculty Member, Duke-Margolis Institute for Health Policy · 2024 - Present Duke-Margolis Institute for Health Policy, University Institutes and Centers

Recent Publications


Comprehensive Medication Reviews in Medicare Were Not Associated With Reduced Central Nervous System-Active Polypharmacy in 2021.

Journal Article J Am Geriatr Soc · December 27, 2025 BACKGROUND: Central nervous system (CNS)-active polypharmacy is associated with increased risks such as impaired cognition and falls. In 2021, CNS-active polypharmacy was added as a Medicare Part D display measure to monitor for this risk. Enrollees in the ... Full text Link to item Cite

A primer on prescription drug pricing benchmarks in the United States.

Journal Article J Manag Care Spec Pharm · December 2025 The price of a prescription drug can be difficult to determine in the United States. Pricing benchmarks are reference points used to determine acquisition costs as drugs are physically moved through the supply chain, to reimburse pharmacies, to calculate r ... Full text Open Access Link to item Cite
View All Publications

Recent Grants


Deprescribing Decision-Making using Machine Learning Individualized Treatment Rules to Improve CNS Polypharmacy

ResearchAdvisor · Awarded by National Institutes of Health · 2024 - 2029

RECONJOINT: A Decision Tool for Patient-Centered Breast Reconstruction Care

ResearchCo Investigator · Awarded by Memorial Sloan-Kettering Cancer Center · 2024 - 2026

Heterogeneity in Medication Therapy Management Used to Reduce Potentially Inappropriate Medication Use

ResearchPrincipal Investigator · Awarded by University of Massachusetts Medical School · 2024 - 2025

View All Grants

Education, Training & Certifications


University of Maryland, Baltimore · 2018 Ph.D.
University of Maryland, Baltimore · 2016 M.S.
University of Maryland, Baltimore · 2014 Pharm.D.
University of Maryland, College Park · 2010 B.S.